Hope Bancorp (HOPE) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on October 28, 2024, might help the stock move higher if these key numbers are better tha ...

SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, announced today that the Company will present the three-year safety and efficacy results from its HOPE-2 open-label extension (OLE) study with lead asset deramiocel for treating Duchenne muscular dystrophy (DMD). The data will highlight the long-term, multi-modal benefits of deramiocel in a late-breaking p ...

Free financial counseling expands in Kentucky one year after the launch of mobile sports betting Partnership with leading organization dedicated to providing access to financial education and empowerment aims to help individuals understand how to best manage their personal finances for long-term financial security NEW YORK, Sept. 17, 2024 /PRNewswire/ -- FanDuel, the premier online gaming company in North America, today announced a second $1 million donation to Operation HOPE, the nation's leading non-profi ...

Funding will Support Youth Impacted by Domestic Violence Across the State RALEIGH, N.C., Sept. 4, 2024 /PRNewswire/ -- WellCare of North Carolina (WellCare), a Medicaid health plan and a Centene Corporation (NYSE: CNC) company, announced today a $100,000 donation available to nine Family Justice Centers across North Carolina. These funds will support Camp HOPE America, a weeklong overnight camp specially designed for youth impacted by domestic violence and trauma. Wellcare of NC (PRNewsfoto/WellCare of Nort ...

Hope Bancorp (HOPE) came out with quarterly earnings of $0.22 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.32 per share a year ago. These figures are adjusted for non-recurring items. This operator of Central Pacific Bank is expected to post quarterly earnings of $0.48 per share in its upcoming report, which represents a year-over-year change of -9.4%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. There are no easy answers t ...

HOPE BANCORP REPORTS 2024 SECOND QUARTER FINANCIAL RESULTS "During the 2024 second quarter, our net interest margin expanded, our operating expenses decreased, and our return on assets improved, compared with the 2024 first quarter," said Kevin S. Kim, Chairman, President and Chief Executive Officer. "These highlights reflect continued progress towards improving our financial performance following our strategic reorganization in the fourth quarter of last year. "Following the signing of the definitive merge ...

Core Viewpoint - Capricor Therapeutics is advancing its drug CAP-1002 for the treatment of Duchenne Muscular Dystrophy (DMD), with significant upcoming milestones that could impact its market position and shareholder value [9][16]. Market Opportunity - The global DMD treatment market is projected to reach $8.19 billion by 2029, with potential for CAP-1002 to capture market share if approved [3]. - The company estimates the DMD market could reach $27 million by 2030, indicating substantial growth potential [3]. Clinical Development - CAP-1002 is currently undergoing a phase 3 trial (HOPE-3) with a primary endpoint focused on the Upper Limb test score over 12 months [3]. - A successful interim futility analysis has allowed the trial to continue as planned, indicating positive progress [10]. - The FDA has agreed to a pre-BLA meeting, positioning the company to file a rolling Biologics License Application (BLA) in Q3 2024 [3][9]. Competitive Landscape - CAP-1002 will face competition from existing therapies, including Sarepta Therapeutics' Elevidys, which received FDA Accelerated Approval but is pending full approval [4]. - Capricor aims to position CAP-1002 as a best-in-class cell therapy due to its multifaceted treatment capabilities, including immunomodulatory and antifibrotic effects [4]. Expansion Opportunities - The company targets late-stage DMD patients, with a potential market of 7,500 to 10,000 patients in the U.S. [5]. - There is an opportunity to expand CAP-1002's application to Becker Muscular Dystrophy (BMD), which could address an additional 5,000 patients in the U.S. [5]. - Capricor is also exploring a multivalent exosome-based vaccine for SARS-CoV-2, with a phase 1 study expected to begin in late 2024 [5]. Financial Position - As of March 31, 2024, Capricor had cash and equivalents of $39.9 million, bolstered by a $10 million payment from a commercialization agreement [6]. - The company anticipates sufficient cash runway to fund operations into Q1 2025, excluding potential milestone payments [6][14].

Commission File Number: 000-50245 HOPE BANCORP, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) Delaware 95-4849715 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (D) OF THE SEC ...

The Company's tier one leverage and risk-based capital ratios were 11.58% and 28.84%, respectively, and the Company is considered to be "well-capitalized" at March 31, 2024.Ratio of non-performing assets to total assets of 0.10% at March 31, 2024.Strong liquidity position with $90 million in cash balances and access to liquidity totaling $901.70 million as of March 31, 2024. HONOLULU, Hawaii, May 03, 2024 (GLOBE NEWSWIRE) -- Territorial Bancorp Inc. (NASDAQ:TBNK) (the "Company"), headquartered in Honolulu, ...

2024 First Quarter Earnings Conference Call Forward Looking Statements & Additional Disclosures Additional Information and Where to Find It Q1 2024 Financial Overview Total Deposits at 3/31/24 Gross Loans at 3/31/24 NPA/Total Assets at 3/31/24 1Q24 Net Income & EPS $27.4MM / $0.23 Excl. notable items • Total capital ratio was 14.19% at 3/31/24, +27bps QoQ. All regulatory capital ratios expanded QoQ • Tangible common equity ("TCE") ratio(1) was 9.33% at 3/31/24, +47bps QoQ • Announced signing of definitive m ...